Mazor Robotics stock rating upgraded to ‘outperform’ after Medtronic agreement: 5 points

Following on the heels of the commercial and investment agreement with Medtronic, Wells Fargo upgraded Mazor Robotics to an “outperform” rating, according to a report by The Market Digest.

Advertisement

Here are five points:

 

1. Wells Fargo had previously rated the company “market perform.”

 

2. Mazor Robotics generated revenues of $6.4 million for the first quarter of 2016, a 42 percent increase from $4.5 million for the same period last year.

 

3. The company also reported United States-generated revenue more than doubled to $5.6 million in this quarter, from $2.7 million in 2015’s first quarter.

 

4. The company has a market cap of $226 million.

 

5. The new deal with Medtronic includes the co-promotion and development and distribution of Mazor products. Medtronic also made an equity investment in Mazor.

 

More articles on devices:
Histogenics acquires sole development, marketing rights for NeoCart in Japan: 5 key notes
Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points
Medtronic invests in Mazor, inks commercial agreement: 6 things to know

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.